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Inclusion complexes of carvedilol(CR) with hydroxyl propyl beta-cyclodextrin (HPBCD) was prepared 
using co-grinding technique. Then, the inclusion complex was microencapsulated using combinations of 
Eudragit NE30D (EU) and sodium alginate (SA) utilizing orifice gelation technique. The formulations 
were analysed by using Scanning electron microscopy (SEM), Fourier Transform Infrared spectroscopy 
(FTIR), Differential scanning Calorimetry (DSC) and X-ray diffractometer (XRD) and also evaluated for 
particle size, encapsulation efficiency, production yield, swelling capacity, mucoadhesive properties, zeta 
potential and drug release. The microcapsules were smooth and showed no visible cracks and extended 
drug release of 55.2006% up to 12 hours in phosphate buffer of pH 6.8, showing particle size within the 
range of 264.5-358.5 µm, and encapsulation efficiency of 99.337±0.0100-66.2753±0.0014%.The in vitro 
release data of optimized batch of microcapsules were plotted in various kinetic equations to understand 
the mechanisms and kinetics of drug release, which followed first order kinetics, value of “n” is calculated 
to be 0.459 and drug release was diffusion controlled. The mice were fed with diet for inducing high 
blood pressure and the in vivo antihypertensive activity of formulations was carried out administering 
the optimized formulations and pure drug separately by oral feeding and measured by B.P Monwin IITC 
Life Science instrument and the results indicated that the bioavailability of carvedilol was increased both 
in vitro and in vivo with the mucoadhesive polymers showing primary role in retarding the drug release.
Uniterms: Carvedilol/microcapsules/evaluation. Carvedilol/microcapsules/formulation. Eudragit 
NE30D. Orifice Gelation technique.
Prepararam-se complexos de carvedilol (CR) com hidroxipropil beta-ciclodextrina (HPBCD), utilizando 
a técnica de co-moagem. O complexo de inclusão foi microencapsulado empregando-se associações 
de Eudragit NE30D (EU) e alginato de sódio (AS), utilizando a técnica de gelificação de orifício. As 
formulações foram analisadas utilizando-se microscopia eletrônica de varredura (SEM), espectroscopia no 
infravermelho com Transformada de Fourier, calorimetria diferencial de varredura (DSC) e difratometria de 
raios X (XDR) e, também, avaliadas por tamanho de partícula, eficiência de encapsulação, rendimento de 
produção, capacidade de inchamento, propriedades mucoadesivas, potencial zeta e liberação do fármaco. 
Obtiveram-se microcápsulas lisas e sem fendas visíveis, com liberação prolongada do fármaco de 55,2006% 
em 12 horas em tampão fosfato pH 6,8, com tamanho de partículas na faixa de 264,5-358,5 mm e eficiência 
de encapsulação de 99,3337±0,0100-66,2753±0,0014%. Os dados de liberação in vitro de lote otimizado 
de microcápsulas foram plotados em várias equações cinéticas para se entender os mecanismos e a cinética 
de liberação do fármaco, que é de primeira ordem, o valor de “n” foi de 0,459 e a liberação do fármaco 
foi por difusão controlada. Os camundongos foram alimentados com dieta para induzir pressão sanguínea 
alta e a atividade anti-hipertensiva in vivo das formulações foi obtida por administração de formulações 
otimizadas e fármaco puro, separadamente, por via oral e medida pelo equipamento BP Monwin IITC Life 
Science. Os resultados mostraram que a biodisponibilidade do carvedilol aumentou tanto in vitro quanto in 
vivo com os polímeros mucoadesivos, mostrando papel principal no retardamento da liberação do fármaco. 
Unitermos: Carvedilol/microcápsulas/avaliação. Carvedilol/microcápsulas/formulação. Eudragit NE30D. 
Técnica de gelificação de orifício.
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INTRODUCTION
The most desirable and convenient method of 
drug administration is the oral route (Patil et al., 2009). 
Carvedilol (CR) is a nonselective β-adrenergic blocking 
agent with α1-blocking activity. It is well absorbed from 
the gastrointestinal tract but subjected to considerable first-
pass metabolism in the liver (Tanwar, Chauhan, Sharma, 
2009) and its oral bioavailability in humans is only 20% 
(Guarve et al., 2009). The drug has a short half-life of 2.2 
± 0.3 h. The drug is formulated with a series of polymers 
to improve the absorption and prolong the half life, thereby 
preventing degradation in gastric region. Since the drug 
has low bioavailability due to poor water solubility and 
slow dissolution rates (Hirlekar, Kadam, 2009) several 
methods are used to improve the solubility profile of 
CR, of which complexation with cyclodextrins has been 
widely used to improve the solubility and dissolution rate 
of poorly soluble drugs (Wang et al., 2006; Archontaki 
et al., 2002). Cyclodextrins (CDs) are macrocyclic 
oligosaccharides with six to eight D-glucose units called 
α-Cyclodextrin, β-Cyclodextrin and γ-Cyclodextrin. 
The most important property of CDs is that they have 
hydrophobic central cavities capable of forming stable 
complexes with properly sized drug molecule (Vyas, Saraf, 
Saraf2008; Shewale et al., 2008; Bhutani et al., 2007). 
Among the various CDs, hydroxypropyl beta-cyclodextrin 
(HPBCD) is most successful in improving the dissolution 
rate (Pitha et al., 1986) of poorly soluble drugs.
Polymeric microparticles are recommended for 
oral, nasal or pulmonary administration. These systems 
are able to promote extended release of a bioactive 
compound and also can protect the drug from degradation 
and physiological metabolism (Salsa, Veiga, Pina1997). 
In order to develop microcapsules, several polymers both 
from natural and synthetic sources can be used (Deasy 
1984).
The present work is mainly focussed on improving 
the solubility characteristics of CR by use of CDs, mainly 
HPBCD by formation of binary systems of CR/ HPBCD 
in a 1:1 ratio (w/w ratio) and then formulating this 
binary system in the form of microcapsules using Orifice 
Gelation technique, by the use of some mucoadhesive 
hydrophilic polymers like Sodium alginate and an aqueous 
dispersion of Eudragit NE30D for oral use. The optimized 
microcapsules were then evaluated in vitro to determine 
the drug release and in vivo to determine the efficacy of 
the formulations.
MATERIAL AND METHODS
Material
Carvedilol(CR) was kindly gifted by Glenmark 
Pharmaceuticals (Mumbai,India), hydroxylpropyl beta-
cyclodextrin (HPBCD) was kindly gifted by Roquette 
(Lestrem, France), sodium alginate (SA) was purchased 
from Loba Chemicals(India); Eudragit NE30D (EU) was a 
gift sample from Evonik Degussa Rohm Pharma (Mumbai, 
India). All other chemicals used were of analytical reagent 
grade purity.
Preparation of Microcapsules
The method used for the preparation of microcapsules 
adopted was Orifice Gelation technique (Chowdary. Rao, 
2003). Binary system of HPBCD/CR was prepared by 
co-grinding technique (Hirlakar, Kadam 2009) in which 
mixing of CR in a ratio of 1:1(w/w ratio) with HPBCD 
in a glass mortar for 30 minutes was done , and stored in 
a desiccator. Then this binary system was mixed with SA 
and EU separately for formulating different batches of 
microcapsules as stated in Table I. The physical mixtures 
(PM) (of the CR along with HPBCD, SA and Eudragit 
NE30D) were analyzed separately for any possible drug-
TABLE I - Composition of formulations
Formulation Code
Drug (carvedilol): 
hydroxypropyl beta-
cyclodextrin (HPBCD) 
(mg)
sodium alginate(SA) 
(mg)
Eudragit NE30D(EU) 
(mg)
CRSAEU1 1:1 600 200
CRSAEU2 1:1 600 400
CRSAEU3 1:1 600 600
CRSAEU4 1:1 200 600
CRSAEU5 1:1 600 1050
CRHPSAI 1:1 1000 --------------
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excipient interactions. The binary system of HPBCD/
CR was triturated with SA and then mixed with Eudragit 
NE30D in a glass mortar pestle and dispersed this mixture 
in milipore water (obtained from Elix milipore water filter) 
using magnetic stirrer for 30 min at 200 rpm and allowed 
to form uniform slurry named as “CRV”. A 3%w/v calcium 
chloride solution was prepared and filtered separately and 
to this solution, the slurry “CRV” was added dropwise 
through a 10 mL syringe (Dispovan) having needle of 
size no.26G .The microcapsules formed were allowed 
to remain in the calcium chloride solution for 30 min to 
complete the curing reaction. The formed microcapsules 
were filtered and washed with millipore water to remove 
any traces of calcium chloride from the microcapsule 
surfaces and dried the microcapsules in open air and kept 
in a desiccator.
Evaluation of microcapsules
Determination of Yield of Production
The production yields (Ranjha, Khan, Nazeem, 
2010) of microspheres of various batches were calculated 
using the weight of finally dried microspheres with respect 
to the initial total quantity of the drug and polymer used 
for preparation. Percent production yields were calculated 
as per the formula below:
Determination percentage encapsulation efficiency
Percentage encapsulation efficiency is the percentage 
of drug encapsulated in the microcapsules related to the 
initial quantity of the drug used in the formulation. 100 mg 
of microcapsules were taken and crushed in a glass 
mortar-pestle. In a 100 mL volumetric flask, the grounded 
microcapsule powder was mixed with methanol to make 
up the volume up to 100 mL and placed the whole system 
in a sonicator for 30 min to get the maximum extraction 
of CR in the solvent. The sample so obtained were filtered 
to obtain clear solution and assayed for the drug content 
spectrophotometrically at 242 nm. Percent encapsulation 
efficiency (Ranjha, Khan, Nazeem, 2010) was determined 
by using the formula below.
·	 Particle Size
The Particle size of the dried microcapsules was 
measured using a stage micrometer scale by optical 
microscopy method. This study was done in triplicate. 100 
nos. of dry microcapsules were placed on a clean glass 
slide and a few drops of liquid paraffin was added and 
covered with a glass slide and observed under a compound 
microscope using stage and ocular micrometer (Dhaliwal 
et al., 2008; Patil et al., 2009).
·	 Determination of bulk density
The bulk density of the formulations was determined 
by using the following formula (Ranjha, Khan, Nazeem, 
2010). This study was done in triplicate.
·	 Determination of Tapped density
Tapped Density is used to investigate packing 
properties of microcapsules into capsules. The Tapped 
density was measured by employing the conventional 
tapping method using a 10ml measuring cylinder and the 
number of tapings was 100 as sufficient to bring a plateau 
condition. This study was done in triplicate. Tapped 
density was calculated by using the following formula 
(Ranjha, Khan, Nazeem, 2010):
 
·	 Determination of Carr’s consolidation Index
It is indirect measurement of bulk density, size and 
shape, surface area, moisture content and cohesiveness of 
materials since all of them can influence the consolidation 
index. It is also called as Compressibility index (Ci). 
This study was done in triplicate. It is denoted by Ci and 
is calculated using the formula below (Ranjha, Khan, 
Nazeem, 2010):
A Carr’s index less than 15% is referred to as very 
good flow,16-26% is good, 27-35% is fairly good and 
℘35% are considered as poor (Carr, 1965).
·	 Determination of Hausner’s ratio
It is another parameter for measuring flowability of 
the microcapsules. This study was done in triplicate. It is 
calculated using the following formula (Ranjha, Khan, 
Nazeem, 2010):
·	 Determination of Angle of repose 
Angle of repose (q=tan-1 h/r) of the microcapsules 
was determined by passing the microcapsules through 
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the glass funnel on a horizontal surface (Ranjha, Khan, 
Nazeem, 2010). This study was done in triplicate .The 
height (h) of the heap formed was measured and the radius 
(r) of the cone base was also observed and calculated.
·	 Percentage of swelling of Microcapsules
Swelling rate of the microcapsules was measured as 
a function of water uptake. The formulations were placed 
in phosphate buffer of pH 6.8 at room temperature for a 
time period of 10hours. At different time intervals, the 
microcapsules were taken out and very gently pressed 
with a tissue paper to remove the excess liquid and then 
weighed. These studies were done in triplicate. The 
percentage swelling of the microcapsules was determined 
by using the following formula as below (Patil Sanjay, 
Sawant Krutika , 2009):
 
·	 Mucoadhesion properties of the microcapsule
Bioadhesive strength of the microcapsules was 
measured on a modified physical balance using the 
method described by Gupta, Garga and Khar(1992). 
Carbopol 934P which was taken as standard to compare 
the mucoadhesivity of microcapsules. The microcapsules 
were sandwiched between two mucosal surfaces of rat 
intestine. The intestine were placed on two oppositely 
placed platforms of two slides ,one hanged to the left pan 
of balance and other placed on a water bath at the base. 
Then weights were placed to the right pan of the balance 
in ascending order starting from lower weights and after 
each addition of weights, allowing to stand for 1min, and 
then added the next weight and this process was continued 
till the two mucosal surfaces detached from one another on 
the left side of pan and thus the detachment force required 
to separate two glass slides was measured. This study was 
done in triplicate.
In vitro Drug release of microcapsules
900 mL of phosphate buffer of pH6.8 (Hirlekar, 
Kadam, 2009) was taken as dissolution medium for in 
vitro drug release in USP Type-I dissolution apparatus. 
100mg of the microcapsules were taken and filled in a 
hard gelatin capsule and placed in the basket and started 
the dissolution at 75 rpm and continued the study for a 
period of 13 hours. 5ml of sample was withdrawn after 
every 0.5,1,2,3,4,5,6,7,8,9,10,11,12,13 hours and analyzed 
spectrophotometrically at 241 nm and calculated the 
cumulative drug release and calculated the drug release 
kinetics. This study was done in triplicate. The statistical 
ANOVA analysis of the in vitro release studies is also 
plotted.
Data obtained from in vitro release studies were fitted 
to various kinetic equations to find out the mechanisms of 
the drug release. The kinetic models used were Zero order 
equation, first order Equation, Higuchi equation, Hixson 
Crowell Equation, Peppas-Korsmeyer Equation.
Phyisicochemical evaluations of microcapsules
·	 FTIR spectroscopy (Ranjha, Khan, Nazeem, 2010)
Binary System (HPBCD/ CR)–Polymers interactions 
were studied by FTIR spectroscopy (FTIT Shimadzu 
8400S). Also the spectra for pure drug and drug loaded 
microcapsules were recorded. Samples were prepared in 
KBr disks (2 mg sample in 200 mg of KBr).The scanning 
was 400-4000 cm-1 and the resolution was 2 cm-1.
·	 X-ray powder diffractometry
This technique was carried out to investigate 
the effect of polymers and complexing agent HPBCD 
on the characteristics of the drug after formulation. 
Powdered samples of pure drug, polymers, HPBCD and 
microcapsules were irradiated with monochromatized 
X-rays (Cu-kα) of 30kV and 15mA current in a Rigaku 
analytical XRD (Model Miniflex, Japan).The scanning 
rate employed was 0.20 min-1 of 2θ.The X-ray powder 
diffractometry (X-RD) patterns of the dug and drug loaded 
microcapsules were recorded (Ranjha, Khan, Nazeem, 
2010).
·	 DCS studies of the microcapsule (Ranjha, Khan, 
Nazeem, 2010; 
5 mg weight of samples(Pure drug, Polymers, 
optimized microcapsule) were taken to carry out tests in 
DSC using Aluminium sample pans at a scanning speed of 
10 oC per min form 10 oC-200 oC to detect any interaction 
between drug and polymers.
Morphological studies of microcapsules
The optimized batch of microcapsules used for 
determination of surface morphology were coated by gold 
sputtering technique and observed using the Scanning 
electron microscope (Ranjha, Khan, Nazeem, 2010) 
(Model Jeol Japan; JSM-6390LV).
Determination of zeta potential of microcapsules
The optimized batch of formulation was dispersed 
in phosphate buffer of pH 6.8 and the surface charge (zeta 
potential) was measured by laser doppler anemometry 
using a Zetamaster (Malvern, UK) (Patil Sanjay, Sawant 
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Krutika, 2009). Also the zeta potential of the individual 
polymers and the drug were measured for a comparative 
study.
In vivo animal studies
·	 Animals
Male swiss albino mice weighing from 100-120 g 
were housed in a temperature and light controlled room 
(23±2 oC; 12 hours light/dark cycle), with free access to 
water and food. All the procedures are in agreement to 
the Institutional animal ethical committee, BIT, Mesra, 
Ranchi (vide letter No.CPCSEA approval no: 621/02/ac/
CPCSEA).
Experimental protocol
Eighteen male mice of eight weeks old were 
randomly selected and divided in three groups of 6 
animals each of weight of 20-50 g. Group 1 received pure 
carvedilol (CR); Group 2 received optimized formulation 
CRSAEU5 {at 10 mg/kg (Schaefer et al., 1998)}; Group 3 
was taken as the control (without any drug or formulations, 
only provided with water and normal food). For all the 
three groups initially, before any treatment, the mice were 
acclamatized for 3 days in the warming chamber of the 
B.P Monwin IITC Life Science instrument. On the 4rth 
day, blood pressure was measured by noninvasive tail 
cuff method using B.P Monwin IITC Inc. Life Science 
instrument. Then for one week the animals of Group1 
&2 were given diet as given in Table II for inducing 
Hypertension (Qianli et al., 2004). After one week, the B.P 
was again measured for all the three groups to observe the 
increase in B.P and after confirming that there is induction 
of hypertension, treatment was started with pure drug CR 
and optimized microcapsules batch CRSAEU5 in two 
different groups respectively.
Statistical evaluations for In-vivo studies of optimized 
carvedilol microcapsules in mice
The data of statistical ANOVA one way analysis was 
calculated in Graph Pad software in mice for optimized 
formulations of carvedilol CRSAEU5 is presented in 
Figure 7 and Figure 8. The IITC life sciences Blood 
pressure (B.P) measuring instrument for mice which was 
utilized during the experiment is presented in Figure 9.
RESULTS AND DISCUSSION
Effect of technique on the formation of 
microcapsules
Mucoadhesive carvedilol microcapsules prepared 
by orifice Gelation technique using a mixure of natural 
polymers and aqueous dispersion of ethylcellulose i.e. 
Eudragit NE30D were found to be free flowing and almost 
spherical in shape. The preparation method used was 
advantageous for entrapment of water-insoluble drugs. 
Moreover by formation of binary system of HPBCD/
CR, solubility parameter of drug CR was increased. The 
production of microcapsules varied with different ratios 
of polymers. The results are shown in Table III. The high 
yield of the microcapsules may be due to the entire mass 
TABLE II - Diet Composition for mice for inducing Hypertension 
(Qianli et al., 2004)
Ingredients Amount (mg)
Protein 14
Fat 20
Fiber 0.5
Carbohydrate 10
Mineral Mix 0.35
Vitamin Mix 0.1
NaCl 8
TABLE III - Micromeritic properties along with encapsulation efficiency, %yield and assessment of mucoadhesivity of formulations
Sl. No.
Formulation 
Code
% 
Encapsulation 
efficiency 
(%E.E)
% Yield
Particle Size 
(µm)
Mucoadhesivity 
[Detachment 
Strength 
(N/Cm2)]
Assessment 
of Duration of 
Mucoadhesion 
in (min)
% C.I
Hausner’s 
Ratio
Angle of 
Repose
1 CRSAEU1 66.2753±0.0014 91.1529 317.5±15.08 0.021909 1.4±0.100 9.1±0.152 1.091±0.009 13.2±0.4612
2 CRSAEU2 78.759±0.001 88.6315 335.0±11.527 0.021582 1.5±0.05773 9.1±0.152 1.091±0.009 12.19±0.5411
3 CRSAEU3 82.598±0.0005 81.6 358.5±11.527 0.021909 1.4±0.100 15.96±0.647 1.16±0.0055 12.103±0.3874
4 CRSAEU4 98.8248±0.0012 86.206 291.5±12.527 0.022236 1.5±0.100 25±0.7637 1.25±0.009 15.13±0.39004
5 CRSAEU5 99.337±0.0100 91.636 264.5±7.527 0.023217 1.6±0.100 8.3±0.1301 1.083±0.0012 11.24±0.4652
6 CRHPSAI 65.84±0.080 85.71 358.5±11.527 0.022236 1.33±0.3055 14.3±0.7419 1.14±0.0100 12.0115±0.245
7 Carbopol 934P ------------- ------ --------- 0.0256041 1.5±0.100 ------- ------------ ----------
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of the polymer available for gelation by the crosslinking 
agent. These studies were done in triplicate.
As the drug is water insoluble, so most of the drug 
got entrapped in the polymer matrix resulting higher drug 
content and high percentage encapsulation efficiency. 
Moreover as the amount of both the polymers increased, 
the entrapment efficiency also increased.
Micromeritic properties
As observed in Table III, the particle size of the 
different batches of microcapsules ranged from 264.5-
358.5 µm as determined by optical microscopy method. 
The formulation CRSAEU5 showed the least particle size 
of 264.5 µm±1.527 among the other formulations, showing 
that is a better formulation. Moreover as seen from 
Table III, CRSAEU5 is the superior among all the other 
formulations as the hausner’s ratio, % compressibility 
index and angle of repose is smallest among all the other 
formulations (Ranjha, Khan, Nazeem, 2010). The bulk and 
tapped density data are given in Table IV.
Swelling studies
The results of swelling studies of all the formulations 
as compared to CRHPSAI as shown in Figure 1, indicates 
that with the increase in polymer concentration, the water 
absorption capacity of the formulations also increase. 
These studies were done in triplicate. These studies are in 
confirmation with earlier studies (Xiudong et al., 2004). 
The statistical studies of the optimized formulation 
CRSAEU5 is shown in Figure 2.
Mucoadhesion studies
As observed from the Table III, CRSAEU5 shows 
the highest mucoadhesive property. With the increase 
in both polymer concentrations, there is an increase 
in mucoadhesion. Also this is supported by results of 
assessment of duration of mucoadhesion as cited in Table 
III.As shown in Figure 3, microcapsules adhesioned to 
the rat intestine of 3 cm2 area, where length is 3cm and 
breadth is 1 cm.
In vitro release studies
The in-vitro release studies were carried out in pH 
6.8 phosphate buffer. It was observed that at alkaline pH, 
greater stress was caused to the polymers thereby causing 
release of drugs. The microcapsules swelled excessively 
followed by erosion in the buffered alkaline medium. 
Eudragit NE30D shows the gelling property in alkaline 
medium which is considered beneficial for sustaining 
drug release from the microcapsules. The microcapsules 
TABLE IV - Bulk and tapped density of formulations (Mean ±S.D)
Sl.No. Formulation Code
Weight taken in 
(gm)
Bulk Volume 
(mL)
Tapped Volume 
(mL)
Bulk Density BD 
(g/mL)
Tapped Density TD 
(g/mL)
1 CRSAEU1 1.0 1.2±0.005 1.1±0.005 0.909±0.005 1.2±0.005
2 CRSAEU2 1.0 1.2±0.005 1.1±0.005 0.909±0.005 1.2±0.005
3 CRSAEU3 1.0 0.694±0.002 0.598±0.005 1.666±0.002 0.7±0.005
4 CRSAEU4 1.0 0.9±0.01 1.0±0.011 1.25±0.01 1.0±0.011
5 CRSAEU5 1.0 1.3±0.005 0.769±0.005 0.833±0.005 1.3±0.005
6. CRHPSAI 1.0 0.79±0.006 1.7±0.008 0.555±0.006 0.588±0.008
FIGURE 1 - Comparative % swelling studies of all formulations.
FIGURE 2 - % swelling studies of formulation CRSAEU5 
±S.D, n=3.
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TABLE V - Release kinetics of carvedilol from microcapsules
Sl. No. Formulation Code
Zero order 
Kinetics
First order 
Kinetics
Higuchi 
Kinetics
Hixson Crowell 
Kinetics
Korsmeyer-Peppas 
Kinetics
R2 k0 R2 k1 R2 kH R2 kHC R2 n
1 CRSAEU1 0.964 7.131 0.825 -0.153 0.980 28.69 0.945 -0.278 0.968 0.423
2 CRSAEU2 0.951 6.654 0.763 -0.138 0.980 26.94 0.934 -0.253 0.966 0.443
3 CRSAEU3 0.948 6.678 0.827 -0.135 0.976 27.02 0.926 -0.256 0.968 0.446
4 CRSAEU4 0.967 6.233 0.861 -0.079 0.943 24.56 0.931 -0.188 0.883 0.436
5 CRSAEU5 0.963 3.520 0.967 -0.022 0.966 14.06 0.963 -0.071 0.945 0.459
6 CRHPSAI 0.948 14.01 0.938 -0.250 0.984 40.71 0.991 -0.501 0.993 0.654
showed sustained release for a period of 13 hours due to 
the hindered diffusion of the drug from the gel matrix 
of Sodium alginate and Eudragit NE30D formed in situ 
(Sharma, Sarangi, Pradhan2009) and thereby causing 
retarded drug release. The release of drugs was retarded 
with the increase in the polymer ratio. From the Figure 
3, it is clearly visible that formulation CRSAEU5 has the 
highest property of retarding the drug release. The results 
were compared with Formulation CRHPSAI (devoid of 
Eudragit NE30D) and it is seen that drug release from 
CRHPSAI is 98% within 7 hours. Thus Eudragit NE30D 
is highly effective in retarding the drug release. This study 
was done in triplicate.
 
Kinetics of drug release
Inorder to understand the mechanism and kinetics 
of invitro drug release, the data were analyzed with 
various kinetic equations like Zero order(% Cumulative 
drug release Vs time in hours), First order plot(log 
FIGURE 3 – Comparative Drug Release Profile of microcapsules 
at pH 6.8; CRSAEU4(filled (Diamond,Ser.1),CRSAEU1(Filled 
Square ,Ser.2 ) ,CRSAEU5(Fil led  t r iangle ,Ser ies3 ) , 
C R S A E U 2 ( C ro s s , S e r. 4 ) ,  C R S A E U 3 ( S t a r, S e r. 5 ) , 
CRHPSAI(Filled Circle,Ser.6), Mean % cumulative drug 
release±S.D, n=3
of Cumulative % drug unreleased Vs Time), Higuchi 
model(% Cumulative Drug released Vs Square root of 
time) and Korsmeyer-Peppas Plot (log% Cumulative 
drug released Vs log of time). Coefficient of Correlation 
values were calculated for the linear curves obtained by 
regression analysis of the above plots.
As observed from Figure 3, it is clear that formulation 
CRSAEU5 retards the drug release for a longer period of 
time than in comparison to other formulations, thereby 
controlling the drug release. From Table V, it is clear that, 
CRSAEU5 follows first order release mechanism and 
value of “n” is 0.459 which indicates that the mechanism 
of the drug to diffusion controlled (Sharma, Sarangi, 
Pradhan 2009; Mukherjee et al., 2005).
Surface topography
After considering all the parameters of evaluation 
formulation CRSAEU5 is considered as most efficient. 
Surface morphologies of the formulation CRSAEU5 as 
confirmed by SEM studies shows that there are no cracks 
or crevices present on the surface as shown in Figure 4.
FIGURE 4 - Scanning electron microscopy of CRSAEU5.
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Zeta potential measurement
The Zeta potential value of CRSAEU5 as seen 
from Table VI is found to be more towards the positive 
side than in comparison to the pure drug. The increase in 
zeta potential may be due to the contribution of HPBCD 
and Eudragit NE30D.This increase in zeta potential 
of the formulation also contributes to the increase in 
mucoadhesive property of the formulation as seen in 
Table III. This result is in confirmation with earlier studies 
(Dhawan, Singla, Sinha , 2004).
FTIR analysis
As observed in Figure 5, FTIR studies indicated 
weak interactions of carvedilol with HPBCD at 1:1 ratio 
prepared in the form of microcapsules with different 
polymers as shown in Figure 7. In carvedilol spectra, 
absorption peaks were observed at 3349.7701 cm-1, 
2933.55621 cm-1 due to hydroxyl and amine stretching 
respectively. Other peaks were at 1233.5979 cm -1 
due to C-O group (epoxides),1094.86001 cm-1 due 
to aryl alkyl ethers and alkyl ether C-O stretching 
respectively. Whereas in the PM, there is an exhibition 
at 3339.7409 cm-1, 2913.4977 cm-1 due to hydroxyl 
and amine stretching respectively which matches with 
pure drug. Also there is an exhibition at 1273.715 cm-1, 
1064.77225 cm-1 which matches with that of pure drug 
showing still the presence of aryl alkyl ethers and alkyl 
ether C-O stretching respectively. In case of Formulation 
CRSAEU5, there is appearance of broad wave number 
of 3261.17844 cm-1 indicating the presence of hydroxyl 
stretching, and there is very less intensity of presence of 
1064.77225 cm-1 indicating the entrapment of carbazol 
moiety into host cavity during inclusion complex. The 
results are in confirmation with Hirlekar and Kadam 
(2009).
XRD analysis
The XRD patterns of pure Carvedilol (CR), physical 
mixture (PM), pure HPBCD, formulation CRSAEU5 
are illustrated in Figure 6 and Figure 7. The diffraction 
pattern of the physical mixture is simply superimposition 
or summation of the drug and HPBCD with similar 
sharp peaks.Nevertheless some changes like peak 
locations,reduction in peak intensities were observed in the 
diffractograms of physical Mixture(Table IX) indicating 
the possibility of some kind of interactions between CR 
and HPBCD.The formulation also presented a diffraction 
pattern quite similar to that of physical mixture but with 
much lower intensities.Also there was disapperance of 
diffraction peaks of drug in the formulation CRSAEU5.
Rajashree Hiralkar et al. found the similar results for 
CR-MβCD complexes (Hirlekar, Kadam 2009). These 
phenomena confirmed that an inclusion complex between 
TABLE VI - Zeta potential of optimized formulation, polymers, 
pure drug
Sl.No. Formulation/Polymer/Drug
Zeta potential 
(mV)
1 CRSAEU5 -20.2
2 sodium Alginate -67.3
3 Eudragit NE30D -17.2
4 HPBCD -19.4
5 carvedilol -28.2
FIGURE 5 - FTIR spectra of CRSAEU5, physical mixture (PM), 
HPBCD, carvedilol, sodium alginate, Eudragit NE30D.
FIGURE 6 - X-ray diffractograms of CRSAEU5, 
pure carvedilol, pure HPBCD and amorphous carvedilol.
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the CR and HPBCD.The results in Table VII,showed the 
crystalline characteristics of the drug CR disapperared 
when complexed with HPBCD as seen in CRSAEU5.
Moreover the peak intensities was found to be reduced in 
amorphous CR.
DSC analysis
DSC studies can be used for the recognition of 
inclusion complexes (Hirlekar, Kadam, 2009). When 
the guest molecules were embedded in cyclodextrin 
cavity, their melting point , boiling or sublimation points 
generally shifted to a different temperature (Magnusdottir, 
Masson, Loftsson, 2002). The thermograms of CR along 
with Physical mixtures, formulation CRSAEU5 and Pure 
HPBCD are shown in Figure 8. The thermogram of CR 
was typical of a highly crystalline compound characterized 
by a sharp endothermic peak at 118 oC which corresponded 
to its melting point too (Miro et al., 2006). The DSC 
thermogram of HPBCD showed a broad endotherm 
which attained a maximum around 100 oC due to release 
of water molecules. The PM also did not retain the drug 
endothermic peak and showed a broad peak at 100.91 oC 
which showed that the complex of the drug and HPBCD 
in solution state loses the crystalline properties of the 
drug and thus converts the drug amorphous. Similarly, 
formulation CRSAEU5 showed broad endothermic peak 
at 95-105 oC. This may be due to the shift of characteristics 
peak of CR, which was observed at 117 oC, thereby 
indicating weak interaction of drug CR with HPBCD. This 
indicates that there is formation of an amorphous drug, 
thereby indicating the formation of Inclusion Complex of 
CR in HPBCD.
TABLE VII - Peak intensities of CR in XRD patterns of CR-HPBCD systems
Sl.No. 2θ CR HPBCD
CR:HPBCD
Amorphous CR
PM CRSAD4
1 11.47 102 ----- 36 24 24
2 12.82 158 ------ 78 23 15
3 14.62 130 ------ 118 44 35
4 17.32 630 15 223 92 80
5 24.100 186 10 158 47 16
6 26.110 152 ----- 124 39 44
7 29.170 151 ------ 48 35 ----
FIGURE 7 - X-ray diffractograms of Physical mixtures 
carvedilol with HPBCD in a ratio of 1:1.
F IGURE 8 -  DSC thermograms of  CRSAEU5,  pure 
carvedilol(CR), pure hydroxypropyl beta-cyclodextrin 
(HPBCD), physical mixture (CR+HPBCD+EU) and pure 
Eudragit NE30D(EU).
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Invivo animal studies
The in vivo studies were carried out with the 
optimized formulation CRSAEU5 in Swiss albino mice 
to study the effect of microcapsules. For this purpose, the 
decrease in blood pressure was observed in hypertension 
induced mice (with diet mentioned in Table II), which were 
treated with CRSAEU5 formulation. The results were 
compared with group treated alone with pure drug CR 
and Control group. The effects were observed after 24 h 
from the day of treatment. The data of the blood pressure 
are presented in Figure 9.
From the Figure 9, it is clear that, the microcapsule 
formulation coded as CRSAEU5, was effective in 
decreasing the blood pressure as compared to pure drug 
group. This may be due to the increase in drug solubility 
in the body fluids by inclusion of complexing agent in the 
formulation.
The in vivo statistical ANOVA studies are shown in 
Figure 10, which shows that CRSAEU5 is most effective 
in controlling the hypertension in comparison to the 
pure drug. As the pure drug is lipophilic and very less 
bioavailable, but in the formulation the drug is complexed 
with HPBCD, thus the hydrophilicity of the drug is 
enhanced and thus it becomes more bioavailable.
 
FIGURE 9 – In vivo studies of hypertension in mice.
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CONCLUSIONS
In this study, co-grinding technique has been applied 
to produce inclusion complex of CR with HPBCD and 
then incorporating this inclusion complex in the polymer 
matrix by using orifice gelation technique by use of a 
mixture of polymers Eudragit NE30D and sodium alginate 
which resulted in smooth, free flowing microcapsules 
having improved drug delivery. Higher drug loading 
efficiency was observed for all the formulations, and also 
the drug release was observed for a period of 13 h. Thus 
the polymer Eudragit NE30D, showed promising result 
in retarding drug release. Moreover Eudragit NE30D did 
not show any incompatibility with neither the inclusion 
complex nor with the other polymer, i.e. with sodium 
alginate. Morphological analysis by Scanning Electron 
Microscopy showed that the formulations were almost 
spherical in shape and size. All the analytical studies 
showed that the drug and HPBCD had weak interactions 
leading to inclusion of drug carvedilol in the cyclodextrin 
cavity thereby improving the dissolution profile of the 
drug. The in vivo animal studies showed that the optimized 
formulation was effective in controlling the hypertension 
for a period of 24 h.
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